Описание

Additional IBS symptom outcomes from the synbiotic intervention trial at the 8-week endpoint are displayed.

Figure 7

Chart

Source Paper

The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant …

Nutrients (2020)

PMID: 32635661

DOI: 10.3390/nu12071999

Cite This Figure

![Figure 7: Additional IBS symptom outcomes from the synbiotic intervention trial at the 8-week endpoint are displayed.]()

> Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." *Nutrients*, 2020. PMID: [32635661](https://pubmed.ncbi.nlm.nih.gov/32635661/)

<figure>
  <img src="" alt="Additional IBS symptom outcomes from the synbiotic intervention trial at the 8-week endpoint are displayed." />
  <figcaption>Figure 7. Additional IBS symptom outcomes from the synbiotic intervention trial at the 8-week endpoint are displayed.<br>  Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32635661/">32635661</a></figcaption>
</figure>

Связанные доказательства

Bifidobacterium longum для Irritable Bowel Syndrome (IBS)

Оценка B · 4 исследований

Galactooligosaccharides (GOS) для Irritable Bowel Syndrome (IBS)

Оценка B · 3 исследований

Lactobacillus acidophilus для Irritable Bowel Syndrome (IBS)

Оценка B · 3 исследований

Fructooligosaccharides (FOS) для Irritable Bowel Syndrome (IBS)

Оценка D · 2 исследований